Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is now available for sale within Canada.HaluGen's psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one's psychedelic assisted therapy...

    2021-04-06 8:30 AM ET
  • Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

    Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company's data strategy design, study design and advise on regulatory relationships and data strategy.Ms. Maher has served as an executive and consultant for major...

    2021-03-03 9:30 AM ET
  • Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. ("HaluGen"), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.Following the Company's...

    2021-02-24 9:30 AM ET
  • Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

    Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research organization, Science in Action, an Israeli-based lab specializing in pre-clinical in vivo and in vitro R&D services.Science in Action has confirmed that it has received ethics approval for an in vivo non-GLP...

    2021-02-22 9:30 AM ET
  • Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

    Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer.Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of...

    2021-02-16 9:30 AM ET
  • Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development

    Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna Birgans, a highly experienced media executive and producer, as Vice President of Digital Experience.Mrs. Birgans' significant depth of experience spans wide across the media and entertainment sectors; from creating content and overseeing major media productions for companies including...

    2021-02-04 9:30 AM ET
  • Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

    Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license amendments issued to its clinical research organization, The Centre for Human Drug Research (CHDR).Entheon confirms that the CHDR, the Company's Netherlands-based partner clinical research organization, has received an amendment to its opioid license, enabling it to possess and conduct research with DMT....

    2021-02-02 9:30 AM ET
  • Entheon Biomedical to be Included in First North American Psychedelic ETF

    Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol "PYSK" on the NEO exchange.The Psychedelic ETF invests in North American...

    2021-01-22 9:30 AM ET